Market Maker Surveillance Report. DBLE, IMGN, UWN, SCON, XNPT, HRZ, Winning Stocks With Lowest Price Friction For Thursday, Ap
April 7, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 2371 companies with "abnormal" market making, 1964 companies with positive Friction Factors and 3380 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. DOUBLE EAGLE PETROLEUM CO (NASDAQ:DBLE), IMMUNOGEN INC (NASDAQ:IMGN), NEVADA GOLD & CASINOS INC (AMEX:UWN), SUPERCONDUCTOR TECHNOLOGIES (NASDAQ:SCON), XENOPORT INC (NASDAQ:XNPT), HORIZON LINES INC-CL A (NYSE:HRZ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Friction Factor is shown in the chart below:
Symbol Change Percent Buy Volume Buy %% Sell Volume Sell %% Net Volume Friction DBLE $2.100 22.85% 624,025 57.30% 461,229 42.35% 162,796 775 IMGN $2.500 26.88% 2,692,192 50.03% 2,650,854 49.26% 41,338 165 UWN $0.280 21.21% 112,901 53.25% 79,446 37.47% 33,455 1,195 SCON $0.600 19.74% 1,352,029 59.86% 898,064 39.76% 453,965 7,566 XNPT $3.480 54.55% 13,981,637 53.75% 11,132,381 42.80% 2,849,256 8,188 HRZ $0.260 23.48% 3,288,975 51.05% 2,741,337 42.55% 547,638 21,063Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.
For example, the chart above shows DBLE with a dollar gain Thursday of $2.10000 and a Friction Factor of 775 shares. That means that it only took 775 more shares of buying than selling to move DBLE higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.
DOUBLE EAGLE PETROLEUM CO (NASDAQ:DBLE) - Double Eagle Petroleum Co., an energy company, engages in the exploration, development, production, and sale of natural gas and crude oil primarily in the Rocky Mountain Basins of the western United States. The companys principal properties include the Atlantic rim coal bed natural gas project located in south central Wyoming; the Pinedale Anticline property in the Green River basin of Wyoming; the Wind River basin in central Wyoming; and the Moxa Arch and other areas located in southwest Wyoming. It also holds interest in various properties located in North Dakota, Oklahoma, Texas, and Utah. In addition, Double Eagle Petroleum Co. engages in the transportation of gas through its intrastate gas pipeline. As of December 31, 2009, the company had estimated proved reserves of 89.8 billion cubic feet of natural gas and 419 thousand barrels of oil. It also owned interests in a total of 1,172 producing wells and had an interest in 359,830 gross acres natural gas prone basins of the Rocky Mountains. The company was founded in 1972 and is headquartered in Casper, Wyoming.
IMMUNOGEN INC (NASDAQ:IMGN) - ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkins lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The companys products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.
NEVADA GOLD & CASINOS INC (AMEX:UWN) - Nevada Gold & Casinos, Inc. operates as a developer, owner, and operator of gaming facilities in Colorado and Washington. It owns and operates various properties, including Colorado Grande Casino in Cripple Creek, Colorado; the Crazy Moose Casinos in Pasco and Mountlake Terrace, Washington; Coyote Bob's Roadhouse Casino in Kennewick, Washington; the Silver Dollar Casinos in Seatac, Mill Creek, and Renton, Washington; the Club Hollywood located in Shoreline, Washington; the Royal Casino located in Everett, Washington; and the Golden Nugget Casino located in Tukwila, Washington. The company also holds interest in Buena Vista Development Company, LLC, which is working with the Buena Vista Rancheria of Me-Wuk Indians on a Native American casino project to be developed in the city of Ione, California. Nevada Gold & Casinos, Inc. was founded in 1977 and is based in Houston, Texas.
SUPERCONDUCTOR TECHNOLOGIES (NASDAQ:SCON) - Superconductor Technologies, Inc. engages in the research, development, manufacture, and marketing of infrastructure products for wireless voice and data applications. It provides interference elimination and network enhancement solutions to the commercial wireless industry. The company leverages its key enabling technologies, including RF filtering, HTS materials, and cryogenics to develop applications for advanced RF wireless solutions, power efficient HTS materials, adaptive filtering, and government research and development. Its product lines include SuperLink, a receiver front-end high temperature superconductor wireless filter system that eliminates out-of-band interference for wireless base stations; AmpLink, a ground-mounted unit for wireless base stations that includes a high-performance amplifier and up to 6 dual duplexers; and SuperPlex, a multiplexer that provides low insertion loss and cross-band isolation. The company also grants the Federal government a royalty-free, non-exclusive, and nontransferable license to use its intellectual property. Superconductor Technologies, Inc. sells its products primarily to wireless carriers through direct sales force in the United States, as well as through indirect channels internationally. The company was founded in 1987 and is headquartered in Santa Barbara, California.
XENOPORT INC (NASDAQ:XNPT) - XenoPort, Inc., a biopharmaceutical company, focuses on developing internally discovered product candidates that utilize the bodys natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs. The company licenses its lead product candidate XP13512, a transported prodrug of gabapentin, to Astellas Pharma Inc. in Japan and five Asian countries, as well as to Glaxo Group Limited (GSK) in the United States and internationally. Astellas and GSK filed new drug applications for the approval of XP13512 as a treatment for restless legs syndrome in Japan and the United States. The company also develops Arbaclofen Placarbil, which is under Phase IIb clinical trials for the treatment of gastroesophageal reflux disease. In addition, it develops Arbaclofen Placarbil that has completed Phase II clinical trials for the treatment of spasticity. Further, the company develops XP21279, a transported prodrug of L-Dopa, which has completed Phase I clinical trials for the treatment of Parkinsons disease; and XP21510, a transported prodrug of tranexamic acid, that is in preclinical stages for the treatment of menorrhagia or heavy menstrual bleeding. XenoPort, Inc. has strategic alliances with Astellas Pharma, Inc. and Glaxo Group Limited. The company was founded in 1999 and is based in Santa Clara, California.
HORIZON LINES INC-CL A (NYSE:HRZ) - Horizon Lines, Inc., through its subsidiaries, provides container shipping and integrated logistics services. It ships a range of consumer and industrial items, such as refrigerated and non-refrigerated foodstuffs, household goods, auto parts, building materials, and other materials used in manufacturing. The company offers container shipping services to ports within the continental United States, Puerto Rico, Alaska, Hawaii, Guam, the U.S. Virgin Islands, and Micronesia. Its integrated logistics services comprise rail, truck brokerage, warehousing, distribution, expedited logistics, and non-vessel operating common carrier operations. Horizon Lines, Inc. also offers terminal services. The company operates terminals in Alaska, Hawaii, and Puerto Rico; contracts for terminal services in seven ports in the continental United States; and the ports in Guam, Yantian, and Xiamen, China, as well as Kaohsiung, Taiwan. In addition, it offers inland transportation services. As of December 20, 2009, the company owned or leased approximately 20 vessels and 18,500 cargo containers. Horizon Lines, Inc. serves consumer and industrial products companies, as well as various agencies of the U.S. government, including the Department of Defense and the U.S. Postal Service. The company was founded in 1956 and is based in Charlotte, North Carolina.
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING
SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.
Contact:
BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net